Trials / Completed
CompletedNCT03869476
Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.
Pilot Study for the Development of a Non-invasive Diagnostic Score to Differentiate Between Essential Thrombocythemia, Premyelofibrosis and Myelofibrosis
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 133 (actual)
- Sponsor
- University Hospital, Angers · Other Government
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
Prospective study for the development of a non-invasive score for differentiating prefibrotic myelofibrosis from essential thrombocytosis and overt myelofibrosis.
Detailed description
The diagnostic criteria for myeloproliferative neoplasia have recently been revised in the WHO 2016 classification, which now recognizes a new entity between essential thrombocythemia (TE) and overt myelofibrosis (or primary myelofibrosis): prefibrotic myelofibrosis. Prefibrotic myelofibrosis patients seem to have a poorer prognosis compared to essential thrombocythemia in term of overall survival and myelofibrotic evolution. The dichotomy between these diseases is based on the bone marrow biopsy evaluation and is challenging with a lack of reproducibility showed in the literature. This study aims to develop a diagnostic non-invasive score for differentiating prefibrotic myelofibrosis from essential thrombocytosis and overt myelofibrosis. The parameters studied are : * spleen fibrosis by elastography * plasma cytokines levels * mutationnal landscape by NGS * CD34 circulating cells Bone marrow biopsy were reviewed by 2 anatomopathologists. Number of patients to be enrolled : 130
Conditions
- Myeloproliferative Disorder
- Essential Thrombocythemia
- Primary Myelofibrosis, Prefibrotic Stage
- Primary Myelofibrosis, Fibrotic Stage
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Non-invasive diagnosis score | * spleen fibrosis by elastography * plasma cytokines levels * mutationnal landscape by NGS * CD34 circulating cells |
Timeline
- Start date
- 2019-07-30
- Primary completion
- 2024-01-30
- Completion
- 2024-01-30
- First posted
- 2019-03-11
- Last updated
- 2024-12-30
Locations
2 sites across 1 country: France
Source: ClinicalTrials.gov record NCT03869476. Inclusion in this directory is not an endorsement.